Trial Profile
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors CJ HealthCare; HK inno.N
- 06 Jul 2021 Primary endpoint (Percentage of patients with complete resolution of main symptoms (heartburn and regurgitation) at 4-week, defined as no episodes of symptom during the last 7 days of treatment, using Reflux Disease Questionnaire(RDQ))has been met. as per Results published in the Alimentary Pharmacology and Therapeutics
- 06 Jul 2021 Results assessing safety and efficacy of tegoprazan compared with those of placebo published in the Alimentary Pharmacology and Therapeutics
- 02 Apr 2018 Status changed from recruiting to completed.